LIVZON PHARMA Appoints Liu Daping as President

Stock News05-29

LIVZON PHARMA (01513) announced that at the 2025 annual general meeting, the board of directors re-elected Mr. Zhu Baoguo, Mr. Lin Nanqi, and Mr. Qiu Qingfeng as non-executive directors of the 12th board. The board re-elected Mr. Tang Yanggang and elected Mr. Liu Daping as executive directors of the 12th board. Furthermore, the board re-elected Mr. Luo Huiyuan, Ms. Cui Lijie, and Ms. Wang Zhiyao, and elected Ms. Kang Li as independent non-executive directors of the 12th board. Following a qualification review by the board's nomination committee, the staff congress democratically elected Ms. Ran Yongmei as an employee representative director of the company's 12th board. In addition, the board agreed to appoint Mr. Liu Daping as the company's president. The board also agreed to appoint Mr. Du Jun, Mr. Xu Xiao, Mr. Chen Zhihua, and Ms. Huang Yuxuan as vice presidents. It agreed to appoint Mr. Wang Sheng as the company's chief financial officer, Ms. Liu Ning as the board secretary and company secretary, and Ms. Xia Yu as the representative for securities affairs at the Shenzhen Stock Exchange.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183768989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183768989","market":"fut","top_or_hot":-1,"title":"LIVZON PHARMA Appoints Liu Daping as President","media":"Stock News","content":"<p>LIVZON PHARMA (01513) announced that at the 2025 annual general meeting, the board of directors re-elected Mr. Zhu Baoguo, Mr. Lin Nanqi, and Mr. Qiu Qingfeng as non-executive directors of the 12th board. The board re-elected Mr. Tang Yanggang and elected Mr. Liu Daping as executive directors of the 12th board. Furthermore, the board re-elected Mr. Luo Huiyuan, Ms. Cui Lijie, and Ms. Wang Zhiyao, and elected Ms. Kang Li as independent non-executive directors of the 12th board. Following a qualification review by the board's nomination committee, the staff congress democratically elected Ms. Ran Yongmei as an employee representative director of the company's 12th board. In addition, the board agreed to appoint Mr. Liu Daping as the company's president. The board also agreed to appoint Mr. Du Jun, Mr. Xu Xiao, Mr. Chen Zhihua, and Ms. Huang Yuxuan as vice presidents. It agreed to appoint Mr. Wang Sheng as the company's chief financial officer, Ms. Liu Ning as the board secretary and company secretary, and Ms. Xia Yu as the representative for securities affairs at the Shenzhen Stock Exchange.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA Appoints Liu Daping as President</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA Appoints Liu Daping as President\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-29 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LIVZON PHARMA (01513) announced that at the 2025 annual general meeting, the board of directors re-elected Mr. Zhu Baoguo, Mr. Lin Nanqi, and Mr. Qiu Qingfeng as non-executive directors of the 12th board. The board re-elected Mr. Tang Yanggang and elected Mr. Liu Daping as executive directors of the 12th board. Furthermore, the board re-elected Mr. Luo Huiyuan, Ms. Cui Lijie, and Ms. Wang Zhiyao, and elected Ms. Kang Li as independent non-executive directors of the 12th board. Following a qualification review by the board's nomination committee, the staff congress democratically elected Ms. Ran Yongmei as an employee representative director of the company's 12th board. In addition, the board agreed to appoint Mr. Liu Daping as the company's president. The board also agreed to appoint Mr. Du Jun, Mr. Xu Xiao, Mr. Chen Zhihua, and Ms. Huang Yuxuan as vice presidents. It agreed to appoint Mr. Wang Sheng as the company's chief financial officer, Ms. Liu Ning as the board secretary and company secretary, and Ms. Xia Yu as the representative for securities affairs at the Shenzhen Stock Exchange.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1183768989","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183768989","pubTimestamp":1780058069,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LIVZON PHARMA (01513) announced that at the 2025 annual general meeting, the board of directors re-elected Mr. Zhu Baoguo, Mr. Lin Nanqi, and Mr. Qiu Qingfeng as non-executive directors of the 12th...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","01513":"丽珠医药"},"translate_title":"丽珠医药任命刘大平为总裁","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"LIVZON PHARMA (01513) announced that at the 2025 annual general meeting, the board of directors re-elected Mr. Zhu Baoguo, Mr. Lin Nanqi, and Mr. Qiu Qingfeng as non-executive directors of the 12th board. The board re-elected Mr. Tang Yanggang and elected Mr. Liu Daping as executive directors of the 12th board. Furthermore, the board re-elected Mr. Luo Huiyuan, Ms. Cui Lijie, and Ms. Wang Zhiyao, and elected Ms. Kang Li as independent non-executive directors of the 12th board. Following a qualification review by the board's nomination committee, the staff congress democratically elected Ms. Ran Yongmei as an employee representative director of the company's 12th board. In addition, the board agreed to appoint Mr. Liu Daping as the company's president. The board also agreed to appoint Mr. Du Jun, Mr. Xu Xiao, Mr. Chen Zhihua, and Ms. Huang Yuxuan as vice presidents. It agreed to appoint Mr. Wang Sheng as the company's chief financial officer, Ms. Liu Ning as the board secretary and company secretary, and Ms. Xia Yu as the representative for securities affairs at the Shenzhen Stock Exchange.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183768989","isCrawlerRequest":true}